Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medical Access Program for Patritumab Deruxtecan (HER3 DXd, U3-1402)

NCT06099639 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06099639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06099639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medical Access Program for Patritumab Deruxtecan (HER3 DXd, U3-1402)
Lead sponsor
Daiichi Sankyo
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

epidermal growth factor receptor (egfr)-mutated non small cell lung cancer